iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Glenmark's Subsidiary Secures Deal for Acne Cream Distribution in Europe and South Africa

27 Sep 2023 , 03:14 PM

Glenmark Pharmaceuticals sees a nearly 2 % increase in morning trade on September 27 after its subsidiary, Glenmark Specialty SA, signed a distribution and license agreement with Cosmo Pharmaceuticals NV for an acne cream in Europe and South Africa. Glenmark gains exclusive rights to commercialize Winlevi (clascoterone cream 1%) in 15 EU countries and South Africa and the UK.

Cosmo will act as the exclusive product supplier, and Cassiopea, a subsidiary of Cosmo, will handle centralizesaw marketing authorisation at the European Medicines Agency (EMA). Winlevi, approved by the US FDA for treating acne in patients aged 12 years and older, has become the most prescribed branded topical acne drug in the US.

Glenmark will pay an upfront amount of $5 million to Cassiopea and additional double-digit regulatory and sales milestones, along with agreed double-digit royalties on net sales. Winlevi’s non-antibiotic approach positions it well to address the EU acne market, projected to grow from $928.7 million in 2021 to $1,297.0 million in 2028, especially considering European guidelines discouraging topical antibiotic use for acne due to the risk of antibiotic resistance.

For feedback and suggestions, write to us at editorial@iifl.com

Related Tags

  • Europe
  • Glenmark
  • news
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.